Stephen A. Ross joins Cytogen Corp. in the newly created position of SVP/sales and marketing.
Ross arrives at the oncology product specialty pharmaceutical company on July 9 from
GlaxoSmithKline, where he has served in various marketing positions for 15 years.
Princeton, N.J.-based Cytogen markets three therapeutic products and one diagnostic product to the U.S.
oncology market. The Company is also developing CYT-500, a third-generation radio labeled antibody to treat prostate cancer.
--Tanya Irwin